Notably, the frequency of CD56+ cells among CCR7+ T cells increased significantly even in relapse-free F-MS patients compared to in HS and nF-MS (p < 0.0001), and increased significantly in relapsed F-MS patients as well (the mean frequency, 26.2% n relapse-free F-MS vs 57.1% in relapsed F-MS, p = 0.0059) (Fig. 2d, right). This evidence concerns the gene NCAM1 and myeloid sarcoma.